Shareholder Tools

Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Mar 10, 2017 Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor indications WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing ...
Mar 2, 2017 WEST LAFAYETTE, Ind., March 02, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Friday, March 10th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update. Investors and the general public are invited to listen to ...
Mar 1, 2017 WEST LAFAYETTE, Ind., March 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Cowen and Company 37th Annual Health Care Conference on Wednesda...
Feb 21, 2017 WEST LAFAYETTE, Ind., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Michael T. Andriole has been appointed as chief financial officer. Mr. Andriole has more than 20 years of experienc...
Dec 1, 2016 WEST LAFAYETTE, Ind., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the IASLC 17th World Conference on ...
Nov 9, 2016 - Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients - - First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical Oncology (ESMO) in October -- Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Nov. 09, 2016 (GLOBE NEWSWIRE) --  End...
Nov 2, 2016 WEST LAFAYETTE, Ind., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 9th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of...
Nov 1, 2016 WEST LAFAYETTE, Ind., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy today announced that the company's management team will present at the 25th Annual Credit Suisse Healthcare Conference on Tuesday, Nov. 8...
Oct 10, 2016 WEST LAFAYETTE, Ind., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, presented poster updates on its two lead clinical programs at the European Society for Medical Oncology (ESMO) 2016 Congress, being held...
Sep 29, 2016 WEST LAFAYETTE, Ind., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented at the European Society for Medical Oncology (ESMO), being held in Copenhagen, Denma...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase